MANAGEMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN CHILDREN AND ADOLESCENTS (SECOND EDITION)
Published by:
Malaysian Health Technology Assessment Section (MaHTAS)
Medical Development Division, Ministry of Health Malaysia
Level 4, Block E1, Precinct 1
Federal Government Administrative Centre 62590
Putrajaya, Malaysia

Copyright
The copyright owner of this publication is MaHTAS. Content may be reproduced in any number of copies and in any format or medium provided that a copyright acknowledgement to MaHTAS is included and the content is not changed, not sold, nor used to promote or endorse any product or service, and not used in an inappropriate or misleading context.

ISBN:

Available on the following websites:
http://www.moh.gov.my
http://www.acadmed.org.my
https://www.psychiatry-malaysia.org

Also available as an app for Android and IOS platform: MyMaHTAS

STATEMENT OF INTENT

These clinical practice guidelines (CPG) are meant to be guides for clinical practice, based on the best available evidence at the time of development. Adherence to these guidelines may not necessarily guarantee the best outcome in every case. Every healthcare provider is responsible for the management of his/her unique patient based on the clinical picture presented by the patient and the management options available locally.

UPDATING THE CPG

These guidelines were issued in 2021 and will be reviewed in a minimum period of four years (2025) or sooner if new evidence becomes available. When it is due for updating, the Chairperson of the CPG or National Advisor of the related specialty will be informed about it. A discussion will be done on the need for a revision including the scope of the revised CPG. A multidisciplinary team will be formed, and the latest systematic review methodology used by MaHTAS will be employed.

Every care is taken to ensure that this publication is correct in every detail at the time of publication. However, in the event of errors or omissions, corrections will be published in the web version of this document, which will be the definitive version at all time. This version can be found on the websites mentioned above.
<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>INTRODUCTION</td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>RISK FACTORS</td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>ASSESSMENT AND DIAGNOSIS</td>
<td></td>
</tr>
<tr>
<td>3.1</td>
<td>Assessment</td>
<td></td>
</tr>
<tr>
<td>3.2</td>
<td>Diagnostic Criteria</td>
<td></td>
</tr>
<tr>
<td>3.3</td>
<td>Investigations</td>
<td></td>
</tr>
<tr>
<td>3.4</td>
<td>Co-morbidities</td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>TREATMENT</td>
<td></td>
</tr>
<tr>
<td>4.1</td>
<td>Psychoeducation</td>
<td></td>
</tr>
<tr>
<td>4.2</td>
<td>Non-pharmacological Treatment</td>
<td></td>
</tr>
<tr>
<td>4.3</td>
<td>Pharmacological Treatment</td>
<td></td>
</tr>
<tr>
<td>4.4</td>
<td>Combination Treatment</td>
<td></td>
</tr>
<tr>
<td>4.5</td>
<td>Dietary Modification</td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>TRADITIONAL AND COMPLEMENTARY MEDICATION</td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>SPECIAL POPULATION</td>
<td></td>
</tr>
<tr>
<td>6.1</td>
<td>Transition</td>
<td></td>
</tr>
<tr>
<td>6.2</td>
<td>Adults</td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>REFERRAL</td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td>MONITORING AND FOLLOW-UP</td>
<td></td>
</tr>
<tr>
<td>9.</td>
<td>IMPLEMENTING THE GUIDELINES</td>
<td></td>
</tr>
<tr>
<td>9.1</td>
<td>Facilitating and Limiting Factors</td>
<td></td>
</tr>
<tr>
<td>9.2</td>
<td>Potential Resource Implications</td>
<td></td>
</tr>
<tr>
<td>REFERENCES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Appendix 1.</td>
<td>Example of Search Strategy</td>
<td></td>
</tr>
<tr>
<td>Appendix 2.</td>
<td>Clinical Questions</td>
<td></td>
</tr>
<tr>
<td>Appendix 3.</td>
<td>Diagnostic and Statistical Manual of Mental Disorder</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fifth Edition (DSM-5)</td>
<td></td>
</tr>
<tr>
<td>Appendix 4.</td>
<td>International Statistical Classification of Diseases and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Related Health Problems, 10th Revision (ICD-10)</td>
<td></td>
</tr>
<tr>
<td>Appendix 5.</td>
<td>Advice for Behavioural Management</td>
<td></td>
</tr>
<tr>
<td>Appendix 6.</td>
<td>School-based Intervention</td>
<td></td>
</tr>
<tr>
<td>Appendix 7.</td>
<td>Pharmacological Treatment of ADHD</td>
<td></td>
</tr>
<tr>
<td>Appendix 8.</td>
<td>Management of Common Adverse Effects Associated</td>
<td></td>
</tr>
<tr>
<td></td>
<td>With Stimulant Use in ADHD</td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>Title</td>
<td>Page</td>
</tr>
<tr>
<td>-----</td>
<td>------------------------</td>
<td>------</td>
</tr>
<tr>
<td></td>
<td>List of Abbreviations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acknowledgement</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Disclosure Statement</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Source of Funding</td>
<td></td>
</tr>
</tbody>
</table>
In line with the current development in CPG methodology, the CPG Unit of MaHTAS is in the process of adapting Grading Recommendations, Assessment, Development and Evaluation (GRADE) in its work process. The quality of each retrieved evidence and its effect size are carefully assessed/reviewed by the CPG Development Group. In formulating the recommendations, overall balances of the following aspects are considered in determining the strength of the recommendations:

- overall quality of evidence
- balance of benefits versus harms
- values and preferences
- resource implications
- equity, feasibility and acceptability

<table>
<thead>
<tr>
<th>Level</th>
<th>Study design</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Evidence from at least one properly randomised controlled trial</td>
</tr>
<tr>
<td>II -1</td>
<td>Evidence obtained from well-designed controlled trials without randomisation</td>
</tr>
<tr>
<td>II-2</td>
<td>Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one centre or group</td>
</tr>
<tr>
<td>II-3</td>
<td>Evidence from multiple time series with or without intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence</td>
</tr>
<tr>
<td>III</td>
<td>Opinions of respected authorities based on clinical experience; descriptive studies and case reports; or reports of expert committees</td>
</tr>
</tbody>
</table>

*SOURCE: US / CANADIAN PREVENTIVE SERVICES TASK FORCE 2001*
KEY RECOMMENDATIONS

The following recommendations are highlighted by the CPG Development Group as the key recommendations that answer the main questions addressed in the CPG and should be prioritised for implementation.

a. Assessment

- Information from parents/carers and teachers should be sought to increase accuracy of the attention-deficit/hyperactivity disorder (ADHD) assessment
- Diagnosis of ADHD should be based on diagnostic criteria of Diagnostic and Statistical Manual of Mental Disorder Fifth Edition (DSM-5) or hyperkinetic disorders from International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10).
- Any child or adolescent presenting with academic difficulties, behavioural problems, mood disturbances, substance use or personality disorders should be evaluated for ADHD to prevent deleterious outcomes in adulthood.

b. Non-pharmacological treatment

- Occupational therapy should be offered as an adjunct in attention-deficit/hyperactivity disorder (ADHD).
- The following individual therapy should be considered in ADHD:
  - organisational skills training
  - cognitive behavioural therapy
- Parent training and behavioural intervention should be offered in ADHD.
- School-based interventions should be offered in ADHD.

c. Pharmacological treatment

- Methylphenidate should be offered to children aged ≥6 years and adolescents with attention-deficit/hyperactivity disorder (ADHD) if medication is indicated.
- If medication for ADHD is indicated in children <6 years old, it should be initiated by a child psychiatrist or a paediatrician with expertise in managing ADHD.

d. Combination treatment

- Combination treatment (pharmacological and non-pharmacological treatment) should be considered in children ≥6 years of age and adolescents with attention-deficit/hyperactivity disorder when the symptoms persist and cause functional impairment.

e. Monitoring

- Healthcare providers should provide continued care and long-term monitoring to children and adolescents with attention-deficit/hyperactivity disorder.
GUIDELINES DEVELOPMENT AND OBJECTIVES
GUIDELINES DEVELOPMENT

The members of the Development Group (DG) for these Clinical Practice Guidelines (CPG) were from the Ministry of Health (MoH) and Ministry of Higher Education. There was active involvement of a multidisciplinary Review Committee (RC) during the process of the CPG development.

A systematic literature search was carried out using the following electronic databases: mainly Medline via Ovid and Cochrane Database of Systemic Reviews and others e.g. PubMed and Guidelines International Network (refer to Appendix 1 for Example of Search Strategy). The search was limited to literature published on humans, "all child (0 to 18 years)" (in most searches), publication from year "2008 to Current" and English language. In addition, the reference lists of all retrieved literature and guidelines were searched and, experts in the field contacted to identify relevant studies. All searches were conducted from 19 Mac 2017 to 18 May 2018. Literature searches were repeated for all clinical questions at the end of the CPG development process allowing any relevant papers published before 21 January 2020 to be included. Future CPG updates will consider evidence published after this cut-off date. The details of the search strategy can be obtained upon request from the CPG Secretariat.

References were also made to other CPGs on attention-deficit/hyperactivity disorder (ADHD) e.g.:  
- Canadian ADHD Practice Guidelines (CAP-Guidelines), 4.1 [Canadian ADHD Resource Alliance (CADDRA), 2020]
- Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents [American Academy of Pediatrics (AAP), 2019]
- Attention deficit hyperactivity disorder: diagnosis and management [National Institute for Health and Care Excellence (NICE), 2018]
- Management of attention deficit and hyperkinetic disorders in children and young people [Scottish Intercollegiate Guidelines Network (SIGN), 2009]

These CPGs were evaluated using the Appraisal of Guidelines for Research and Evaluation (AGREE) II prior to them being used as references.

A total of 14 clinical questions (CQ) were developed under different sections. Members of the DG were assigned individual questions within these sections (refer to Appendix 2 for Clinical Questions). The DG members met 24 times throughout the development of these guidelines. All literature retrieved were appraised by at least two DG members using Critical Appraisal Skill Programme checklist, presented in evidence tables and further discussed in each DG meetings. All statements and recommendations formulated after that were agreed upon by both the DG and RC. Where evidence was insufficient, the recommendations were made by consensus of the DG and RC. This CPG is based largely on the findings of systematic reviews, meta-analyses and clinical trials, with local practices taken into consideration.

The literature used in these guidelines were graded using the US/Canadian Preventive Services Task Force Level of Evidence (2001), while the grading of recommendation was done using the principles of GRADE (refer to the preceding page). The writing of the CPG follows strictly the requirement of AGREE II.

On completion, the draft of the CPG was reviewed by external reviewers. It was also posted on the MoH Malaysia official website for feedback from any interested parties. The draft was finally presented to the Technical Advisory Committee for CPG, and the HTA and CPG Council MoH Malaysia for review and approval. Details on the CPG development methodology by

OBJECTIVES

The objectives of the CPG are to provide evidence-based recommendations on the management of ADHD in the following aspects:
- a. risk factors
- b. diagnosis
- c. treatment
- d. referral and follow-up

CLINICAL QUESTIONS

Refer to Appendix 2.

TARGET POPULATION

1. Inclusion Criteria
Children and adolescents with ADHD (<18 years old)
In certain CQs, evidence is done on adults with ADHD

2. Exclusion Criteria
Management of other disorders with ADHD as co-morbidity is beyond the scope of this CPG.

TARGET GROUP/USERS

This document is intended to guide those involved in the management of ADHD at any healthcare level including:
- i. doctors
- ii. allied health professionals
- iii. trainees and medical students
- iv. patients and their advocates
- v. professional societies

HEALTHCARE SETTINGS

Primary, secondary and tertiary care settings
DEVELOPMENT GROUP

Chairperson
Dr. Nurulwafa Hussain
Consultant Child & Adolescent Psychiatrist
Hospital Melaka, Melaka

Members (in alphabetical order)
Associate Professor Dr. Aili Hanim Hashim
Consultant Child, Adolescent & Adult Psychiatrist
Pusat Perubatan Universiti Malaya
Kuala Lumpur

Dr. Norley Shuib
Lecturer & Psychiatrist
Universiti Teknologi MARA, Selangor

Dr. Akramul Zikri Abd Malek
Psychiatrist
Hospital Kuala Lumpur, Kuala Lumpur

Ms. Ang Wei Nei
Pharmacist
Hospital Selayang, Selangor

Dr. Norharlina Bahar
Consultant Child & Adolescent Psychiatrist
Hospital Selayang, Selangor

Dr. Aili Hanim Hashim
Consultant Child, Adolescent & Adult Psychiatrist
Pusat Perubatan Universiti Malaya
Kuala Lumpur

Ms. Sharlene Teo Shu Lin
Clinical Psychologist
Hospital Tuanku Jaafar, Negeri Sembilan

Dr. Ranjini S Sivanesom
Consultant Developmental Paediatrician
Hospital Tunku Azizah, Kuala Lumpur

Dr. Norley Shuib
Lecturer & Psychiatrist
Universiti Teknologi MARA, Selangor

Ms. Ee Su Im
Occupational Therapist
Hospital Tunku Azizah, Kuala Lumpur

Dr. Selvasingam Ratnasingam
Consultant Child & Adolescent Psychiatrist
Hospital Umum Sarawak, Sarawak

Dr. Eni Rahaiza Muhd Ramli
Consultant Child & Adolescent Psychiatrist
Hospital Taiping, Perak

Datin Dr. Sheila Marimuthu
Consultant Adolescent Paediatrician
Hospital Tunku Azizah, Kuala Lumpur

Dr. Akramul Zikri Abd Malek
Psychiatrist
Hospital Kuala Lumpur, Kuala Lumpur

Dr. Farahidah Md Dai
Consultant Child & Adolescent Psychiatrist
Hospital Sultanah Aminah, Johor

Dr. Tengku Bahiah Tengku Lih
Family Medicine Specialist
Klinik Kesihatan Padang Luas, Terengganu

Dr. Aili Hanim Hashim
Consultant Child, Adolescent & Adult Psychiatrist
Pusat Perubatan Universiti Malaya
Kuala Lumpur

Ms. Sharlene Teo Shu Lin
Clinical Psychologist
Hospital Tuanku Jaafar, Negeri Sembilan

Dr. Selvasingam Ratnasingam
Consultant Child & Adolescent Psychiatrist
Hospital Umum Sarawak, Sarawak

Dr. Farahidah Md Dai
Consultant Child & Adolescent Psychiatrist
Hospital Sultanah Aminah, Johor

Dr. Tengku Bahiah Tengku Lih
Family Medicine Specialist
Klinik Kesihatan Padang Luas, Terengganu

Dr. Norley Shuib
Lecturer & Psychiatrist
Universiti Teknologi MARA, Selangor

Ms. Ee Su Im
Occupational Therapist
Hospital Tunku Azizah, Kuala Lumpur

Dr. Selvasingam Ratnasingam
Consultant Child & Adolescent Psychiatrist
Hospital Umum Sarawak, Sarawak

Datin Dr. Sheila Marimuthu
Consultant Adolescent Paediatrician
Hospital Tunku Azizah, Kuala Lumpur

Dr. Eni Rahaiza Muhd Ramli
Consultant Child & Adolescent Psychiatrist
Hospital Taiping, Perak

Dr. Tengku Bahiah Tengku Lih
Family Medicine Specialist
Klinik Kesihatan Padang Luas, Terengganu

Dr. Noor Ayuni Bazura Muhamad
Senior Principal Assistant Director
Health Technology Assessment Section
Ministry of Health Malaysia, Putrajaya

Dr. Ummu Kalsum Mustapha
Family Medicine Specialist
Klinik Kesihatan Dengkil, Selangor

Dr. Noor Ayuni Bazura Muhamad
Senior Principal Assistant Director
Health Technology Assessment Section
Ministry of Health Malaysia, Putrajaya

Dr. Yusni Yusuff
Consultant Child & Adolescent Psychiatrist
Hospital Sultanah Bahiyah, Kedah

Dr. Noorul Amilin Harun
Child & Adolescent Psychiatrist
Hospital Tengku Ampuan Afzan, Pahang

Dr. Ummu Kalsum Mustapha
Family Medicine Specialist
Klinik Kesihatan Dengkil, Selangor

Dr. Noorul Amilin Harun
Child & Adolescent Psychiatrist
Hospital Tengku Ampuan Afzan, Pahang

Dr. Yusni Yusuff
Consultant Child & Adolescent Psychiatrist
Hospital Sultanah Bahiyah, Kedah
REVIEW COMMITTEE

The draft guidelines were reviewed by a panel of experts. They were asked to comment primarily on the comprehensiveness and accuracy of the interpretation of evidence supporting the recommendations in the guidelines.

Chairperson
Dr. Norhayati binti Nordin
Director & Consultant Child & Adolescent Psychiatrist
Hospital Bahagia Ulu Kinta, Perak

Members
Ms. Chan Pek Har
Clinical Psychologist
Hospital Kuala Lumpur, Kuala Lumpur

Dr. Hazli bin Zakaria
Consultant Psychiatrist
Pusat Perubatan Universiti Kebangsaan Malaysia, Kuala Lumpur

Dr. Izan Hairani binti Ishak
Family Medicine Specialist
Klinik Kesihatan Bukit Kuda, Selangor

Dr. Izzuna Mudla binti Mohamed Ghazali
Public Health Physician
MaHTAS

Dr. Juriza binti Ismail
Consultant Developmental Paediatrician
Pusat Perubatan Universiti Kebangsaan Malaysia, Kuala Lumpur

Professor Dr. Khairani binti Omar
Consultant Family Medicine Specialist
MSU, Shah Alam

Pn. Noor Ratna binti Naharuddin
Head of Pharmacist
Hospital Sultanah Aminah, Johor

Pn. Rokiah binti Alias
Head of Occupational Therapy Department
Hospital Kuala Lumpur, Kuala Lumpur

Associate Professor Dr. Wan Salwina binti Wan Ismail
Consultant Child & Adolescent Psychiatrist
Pusat Perubatan Universiti Kebangsaan Malaysia, Kuala Lumpur
EXTERNAL REVIEWERS (in alphabetical order)

The following external reviewers provided feedback on the draft:
ALGORITHM: MANAGEMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

Symptoms suggestive of ADHD interfering with functioning or development

Assessment by primary care doctors

Refer for further evaluation by Family Medicine Specialist (FMS)

Diagnosis of ADHD

YES

Mild symptoms or functional impairment
Behaviour manageable by parents/teachers

Start non-pharmacological treatment
- Psychoeducation
- Individual-based intervention
- Family-based intervention
- School-based intervention

Improvement

Yes

Continue management and follow-up

No

Persistent impairment despite non-pharmacological intervention

Refer psychiatrist/paediatrician for further management:
- Reassessment
- Pharmacological treatment

NO

Consider other conditions and manage accordingly

Moderate/severe symptoms or functional impairment
- Pre-schoolers
- Indicated for referral*
- Presence of co-morbidities

*Refer Chapter 7 on Referral.
1. INTRODUCTION

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders of childhood. It is defined as a persistent pattern of inattention and/or hyperactive and impulsive behaviour that is more frequent and severe than is typically seen in a child at a given developmental stage. It usually appears in childhood and often lasts into adulthood.

Children and adolescents with ADHD face significant problems in behavioural control, interpersonal relationships, academic performance and personal issues. They had worse health-related quality of life scores than the typically developing groups varying from a small to moderate degree in physical domains and a large degree in psychosocial domains. Therefore, early recognition, assessment and management of this condition is very important in helping them and their parents to improve the educational and psychosocial difficulties.

Worldwide, the estimated prevalence of childhood ADHD is 5.29%. In Malaysia, the estimated prevalence of ADHD range from 1.6% to 4.6%. Boys are three to four times more likely to be diagnosed with ADHD than girls.

This CPG is a full review of the previous edition of guidelines on the management of ADHD published in 2008. It aims to reduce variation in practice and, address advancement in diagnosis and treatment of ADHD. In this edition, a new scope on adult ADHD and transition period into adulthood is addressed because of its growing significance in clinical practice.

2. RISK FACTORS

- ADHD has a multifactorial and complex aetiology which includes both biological and environmental factors.

a. Biological factors
   - Sex
     o Males are associated with increased risk of ADHD (OR=3.05, 95% CI 2.34 to 3.98). This is supported by a recent cohort study of more than 1.5 million individuals in Sweden showing the ADHD ratio between male and female of 3.7:1.
     o Genetics
       o Genetics play a vital role in the aetiology of ADHD with heritability estimate of 76%. The rate of ADHD in relatives of individuals with ADHD compared with the rate of ADHD in relatives of individuals without ADHD is increased with increasing genetic relatedness: - monozygotic twins=70.45 (95% CI 38.19 to 129.96)
         - dizygotic twins=8.44 (95% CI 5.87 to 12.14)
         - full siblings=8.27 (95% CI 7.86 to 8.70)
         - maternal half-siblings=2.86 (95% CI 2.61 to 3.13)
         - paternal half-siblings=2.31 (95% CI 2.07 to 2.58)
         - full cousins=2.24 (95% CI 2.11 to 2.38)
         - half cousins=1.47 (95% CI 1.35 to 1.61)
b. Environmental factors
   - **Pre-pregnancy maternal obesity**
     - Pre-pregnancy maternal obesity (BMI ≥30 kg/m²) is associated with an increased risk of ADHD among children (HR=1.65, 95% CI 1.55 to 1.76). The risk is also increased in overweight women (BMI 25 - 29.9 kg/m²) with HR of 1.27 (95% CI 1.17 to 1.37). Jenabi E et al., 2019, level II-2
   - **Prenatal factors**
     - Hypertensive disorder in pregnancy (HDP)
       - In a meta-analysis, maternal HDP showed a small risk of ADHD in the offspring (OR=1.29, 95% CI 1.22 to 1.36). Maher GM et al., 2018, level II-2
     - Maternal diabetes
       - A recent meta-analysis of six cohort studies demonstrated that maternal diabetes increased the risk for ADHD in offspring (RR=1.40, 95% CI 1.27 to 1.54), with gestational diabetes mellitus showing a higher risk (RR=2.00, 95% CI 1.42 to 2.81). Zhao L et al., 2019, level II-2
       - However, significant publication bias would have overestimate the findings.
     - Maternal psychosocial stress
       - Children born to mothers who experienced a major stressful event during pregnancy or reported a high level of perceived stress are more likely to have ADHD [OR of 1.45 (95% CI 1.06 to 1.99) and OR of 3.03 (95% CI 2.19 to 4.20) respectively]. Okano L et al., 2018, level II-2
     - Maternal cigarette, drug and alcohol use
       - Maternal cigarette smoking, and drug and alcohol abuse are known to be associated with ADHD. SIGN, 2009
       - Maternal smoking during pregnancy is associated with increased risk of ADHD in the offspring: Huang L et al., 2018, level II-2
         - OR in cohort studies of 1.35, 95% CI 1.20 to 1.52
         - OR in case-control studies of 1.85, 95% CI 1.57 to 2.19
     - Maternal paracetamol use
       - A meta-analysis showed that maternal acetaminophen (paracetamol) use during pregnancy was associated with a small risk of ADHD in the offspring (RR=1.25, 95% CI 1.17 to 1.34). The duration of its use for ≥28 days prenatally showed an RR of 1.63, 95% CI 1.23 to 2.16. Gou X et al., 2019, level II-2
       - However the primary papers used in this meta-analysis has heterogenous methodology leading to possible misclassification bias.
     - Maternal antidepressants use
       - Antidepressants use during pregnancy was not associated with increased risk of ADHD (HR=1.2, 95% CI 1.0 to 1.4). Boukhris T et al., 2017, level II-2
     - Maternal use of valproate
       - There is contradictory evidence on the association of maternal valproate use and ADHD. Christensen J et al., 2019, level II-2; Veroniki AA et al., 2017, level II-2
   - **Perinatal factors**
     - Apgar score
       - A lower Apgar score is associated with a higher risk of ADHD in childhood compared with Apgar scores of 9 or 10 at 5 minutes. IJ J et al., 2011, level II-2
       - Apgar scores of 1 to 4 (HR=1.75, 95% CI 1.15 to 2.11)
       - Apgar scores of 5 to 6 (HR=1.63, 95% CI 1.25 to 2.11)
     - Preterm birth and low birth weight
       - Preterm birth is associated with more than twice the risk of developing ADHD, while children with low birth weight have two- to three-fold increased risk. MoH 2008
   - **Traumatic brain injury (TBI)**
     - Children with TBI have higher risk of ADHD (HR=1.32, 95% CI 1.19 to 1.45). Yang LY et al., 2016, level III-2
• Nutritional factors in children
  o There is no association between sucrose consumption and the prevalence of ADHD among children. Del-Ponte B et al., 2019, level II-2
  o To date there is no conclusive evidence that food dyes and food preservatives cause ADHD.

• Screen-time
  Preschool children with more than 2-hours of screen-time/day have an increased risk of ADHD (OR=7.7, 95%CI 1.6 to 38.1). Tamana SK et al., 2019, level II-2

3. ASSESSMENT AND DIAGNOSIS

The assessment and diagnosis of ADHD requires obtaining information from multiple informants, including parents and teachers, as well as conducting a clinical examination on the individual.

ADHD is commonly under-recognised in girls. NICE, 2018 ADHD without hyperactivity (i.e. predominantly inattentive symptoms) is a diagnosis that needs to be considered in girls. Australian CPG, 2009

A meta-analysis on diagnostic accuracy of ADHD using various rating scales revealed that either parents or teachers were able to identify ADHD with a sensitivity of 0.86. On the other hand, reports by both parents and teachers gave a specificity of 0.91. Bied A et al., 2017, level III

3.1 Assessment
a. History
  The clinical history should include the following: AACAP 2007, MoH; 2008
  • core symptoms of ADHD (inattention, hyperactivity and impulsivity) at home, in school and social settings and impact of symptoms
  • age of onset, duration and progression of symptoms i.e. are the symptoms worsening
  • perinatal history, birth and developmental history including development milestones, past medical history (e.g. meningitis, traumatic brain injury, lead toxicity)
  • behaviour in school and academic performance, as well as strengths, weaknesses and possible difficulties or stressors
  • estimated level of intellectual functioning (via a detailed learning and adaptive functioning history)
  • activities of daily living (ADL) functioning (self-care, play and leisure including screen-time, schoolwork and house chores)
  • impact of difficulties and behaviour on the individual i.e. self-esteem, self-worth
  • impact of child’s difficulties and behaviour on family functioning and peer relationships
  • restless, fidgety, disruptive and unsafe behaviours
  • co-morbid psychiatric conditions including changes in mood, appetite, sleep and any substance use
  • medical/social conditions that mimic ADHD symptoms (e.g. autism spectrum disorder (ASD), conditions producing chronic sleep deprivation; obstructive sleep apnoea; neuro-behavioural side effects of medications taken for other chronic conditions; physical, sexual and emotional abuse)
  • family structure and dynamics, parenting styles and expectations
  • family history of ADHD, substance abuse and maternal smoking, parents’ or carers’ mental health e.g. maternal depression
b. Physical and Mental State Examination

A comprehensive physical examination (including vital signs, height and weight) should be performed to exclude physical conditions which mimic ADHD.\textsuperscript{MoH, 2008}

Mental status examination should focus on the following:\textsuperscript{MoH, 2008}
- general appearance and behaviour
- activity level and social interaction
- speech and language
- mood and affect
- thought processes
- attention and concentration
- intelligence and academic skills

c. Rating scales

- Behavioural rating scales are useful adjuncts to the clinical interview in gathering more information about the individual. It should not be used as the sole criterion for clinical diagnosis of ADHD.\textsuperscript{Parker A et al., 2013, level III}
- Common behaviour rating scales used are:
  - Conners’ Rating Scales (CRS)
  - Child Behavioral Checklist (CBCL)
  - Vanderbilt ADHD Rating Scale
  - ADHD Rating Scale 5
  - Strengths and Difficulties Questionnaire (SDQ)

A meta-analysis showed that Conners’ Abbreviated Symptom Questionnaire (ASQ), Child Behavior Checklist-Attention Problem (CBCL-AP) scale and Conners’ Rating Scale–Revised (CRS-R) were effective rating scales to detect ADHD symptoms with sensitivity ranging from 0.75 to 0.83.\textsuperscript{Chang LY et al., 2016, level III}

3.2 Diagnostic Criteria

- ADHD is diagnosed based on diagnostic criteria of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (refer to Appendix 3) or hyperkinetic disorders from 10\textsuperscript{th} Revision of the International Statistical Classification of Diseases and Related Health Problem (ICD-10) (refer to Appendix 4).

The core symptoms of ADHD are:\textsuperscript{DSM-5, ICD-10}
- inattention
- hyperactivity and impulsivity

In order to meet diagnostic criteria, the core symptoms should:\textsuperscript{DSM-5, ICD-10}
- be persistent
- be pervasive (present in two or more setting)
- have caused significant functional impairment
- not better accounted for by other mental disorders (e.g. pervasive developmental disorder, schizophrenia, other psychotic disorders, depression or anxiety)

The onset of symptoms should be before the age of five years for hyperkinetic disorder\textsuperscript{ICD-10} or 12 years for ADHD.\textsuperscript{DSM-5}
• Children and adolescents with signs and symptoms suggestive of ADHD should be referred for assessment and further management.

**Recommendation 1**

- Information from parents/carers and teachers should be sought to increase accuracy of the attention-deficit/hyperactivity disorder (ADHD) assessment.
- Diagnosis of ADHD should be based on diagnostic criteria of Diagnostic and Statistical Manual of Mental Disorder Fifth Edition (DSM-5) or hyperkinetic disorders from International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10).

### 3.3 Investigations

a. **Laboratory tests**

There is no diagnostic laboratory test for ADHD. Laboratory tests should only be performed if there is a clinical indication.

b. **Other investigations**

Electroencephalogram (EEG) and Magnetic Resonance Imaging (MRI) are not indicated in the diagnosis of ADHD.

### 3.4 Co-morbidities

In children with ADHD:

- learning disorders, sleep disorders and oppositional defiant disorders (ODD) are common [Reale L et al., 2017, level III]
- 31% have co-occurring ODD, 10% have conduct disorders (CD) while 3% have both ODD and CD [Bendiksen B et al., 2017, level II-2]
- tic disorder is seen in 10 - 12% [MoH 2008]

In a meta-analysis of 18 cross-sectional studies, girls with ADHD showed higher risk of anxiety (OR=3.19, 95% CI 1.81 to 5.65) and depression (OR=4.21, 95% CI 2.08 to 8.51) compared with those without ADHD. [Tung I et al., 2016, level III] However, there was no mention on inclusion criteria and quality assessment in the meta-analysis.

ADHD or Autism Spectrum Disorder (ASD) in children and adolescents are significantly associated with allergic conditions e.g. allergic rhinitis, allergic conjunctivitis, atopic dermatitis and asthma [Musken JB et al., 2017, level II-2]

• Children with ADHD should be evaluated for co-morbidities.

### 4. TREATMENT

As ADHD is a chronic condition, children and adolescents with ADHD and their families require long-term treatment.

• The goal of treatment is to improve symptoms, functioning and learning. It also aims to increase the child’s self-esteem and self-worth. The treatment includes non-pharmacological and/or pharmacological approaches.
• In view of difficulties with diagnosis and special requirements of management, preschoolers (children below six years old) suspected of ADHD should be referred to a child psychiatrist or a paediatrician.

4.1 Psychoeducation

In a systematic review, psychoeducation demonstrated positive outcomes in children and adolescents with ADHD with regards to: Montoya A et al., 2011, level I
• significant reduction of core ADHD symptoms
• excellent adherence to medical recommendations
• reduction in fears associated with medication usage (including side effects)
• improvements in academic achievements
Psychoeducation also improved maternal well-being.

Parents' perceptions of ADHD and treatment acceptability are the main barriers to medication adherence. An early structured psychoeducation programme provides a new approach in improving medication adherence and clinical symptoms of ADHD children in the clinical setting. Bai GN et al., 2015, level I

Psychoeducation should ideally contain the following:
• a good patient-healthcare provider relationship
• disorder-related information e.g. symptoms, potential causation/risk factors and negative effects in the life course
• treatment-related information outlining pharmacological and non-pharmacological approaches, particularly regarding the effectiveness and adverse effects of medication
• barriers to adherence and coping skills
• parenting skills

4.2 Non-pharmacological Treatment

There are many non-pharmacological therapies available for individuals with ADHD. They differ in names and, have different techniques and strategies. However, they share a set of principles to achieve the same aims.

4.2.1 Individual Therapy

a. Occupational therapy

Occupational therapy is one of the supporting therapies in the management of ADHD. Therapeutic methods recommended include sensory motor activities, motor training, social skill training, cognitive interventions, behaviour intervention and play-based interventions. Nielsen SK et al., 2017, level I; Wilkes-Gillan S et al., 2016, level I

A systematic review on the effectiveness of occupational therapy interventions for school-aged children with ADHD showed: Nielsen SK et al., 2017, level I
• cognitive interventions
  o cognitive orientation to daily occupational performance (CO-OP) improved motor performance
  o family-centered intervention improved behavioural outcome and parental perception
• motor interventions
  o three-dimensional fine motor training significantly improved speed and consistent letter shapes in handwriting
  o Theraplay intervention significantly improved visual motor integration
• sensory interventions
o weighted vests improved attention and on-task behaviour
o stability balls improved in-seat and on-task behaviour

• play based interventions
  o Theraplay intervention reduced ADHD symptoms and, enhanced relationships and child’s overall performance
  o play-based intervention improved playfulness and interpersonal empathy
  o parent-delivered intervention increased play skills
  o social skills training improved communication, interactions skills and improve process skills

In local settings, occupational therapy is a useful adjunct intervention in the management of ADHD.

b. Organisational skills training
Organisational skills deficits in children with ADHD are shown to impair academic performance and may be associated with psychosocial, occupational and economic difficulties later in life. These children frequently have problems dealing with school materials and completing school assignments on time.

In a meta-analysis of 12 RCTs, organisational skills training was more effective than control in improving organisational skills and the ratings of inattention and academic performance of children with ADHD.\textsuperscript{3} Bikic A et al., 2017, level I

- parent-reported organisational skills (Hedge’s $g=0.830$, 95% CI 0.324 to 1.336)
- teacher-reported organisational skills (Hedge’s $g=0.539$; 95% CI 0.169 to 0.909)
- parent-reported attention (Hedge’s $g=0.558$, 95% CI 0.379 to 0.736)
- teacher-reported attention (Hedge’s $g=0.264$, 95% CI 0.006 to 0.522)
- teacher-reported academic performance (Hedge’s $g=0.326$, 95% CI 0.143 to 0.508)

c. Psychological intervention
Cognitive behavioural therapy (CBT) is one of the psychological interventions that has been proposed in the treatment of ADHD. A good meta-analysis showed modest effectiveness of CBT in reducing externalising symptoms in children with ADHD (Cohen’s $d=-0.549$, 95%CI -0.774 to -0.324).\textsuperscript{4} Battagliese G et al, 2012, level I

In a cross-over RCT, an eight-month assessment showed CBT was effective for adolescents with ADHD who continued to exhibit persistent symptoms despite medications.\textsuperscript{5} Sprich SE et al., level I

CBT sessions include modules on psychoeducation and organisational/planning, distractibility, adaptive thinking, procrastination and relapse prevention.\textsuperscript{6} Sprich SE et al., level I These sessions should be conducted by trained personnel.

Mindfulness-based intervention (MBI) is a promising strategy to reduce ADHD symptoms.\textsuperscript{7} Xue J et al., 2019, level I

A meta-analysis demonstrated MBI was effective in children with ADHD in terms of reduction in inattention (Hedges’ g= -0.825, 95% CI -1.161 to -0.488)

However, the above results must be interpreted with caution because of high heterogeneity across the studies ($I^2=69.10$ to 76.24%).

d. Assistive technology
There is no strong evidence for assistive technology in ADHD. The use of fidget spinner is associated with only temporary decrease in gross motor activity (Cohen’s $d=-0.44$, $p<0.05$). It worsens attentional functioning (Cohen’s $d=0.65$, $p<0.001$). \textsuperscript{8} Graziano PA et al., 2018, level II-3
4.2.2 Family-based Intervention

Parent training and behavioural intervention

Parents often experience high levels of stress in handling children with ADHD and their associated impairments. Stress may affect parenting effectiveness, quality of parent-child relationships and the child’s functioning.

Adolescents with ADHD and their parents reported more parent–adolescent conflicts. Parents of adolescents with ADHD reported a greater intensity of anger in the parent–adolescent communication. They also reported having their own conflicts and mental health issues. Lee YC, 2016, level III

Parent training and behavioural interventions improve parenting skills Charach A et al., 2013, level I and reduce parenting stress Zwi M et al., 2011, level I Parent training assists parents to understand and support the child, cope with stressful situations and encourage appropriate behaviours. It helps parents to modify and shape their child’s behaviour while improving the child’s ability to regulate his or her behaviour.

In children with ADHD, parent training and behavioural interventions:

- reduce ADHD symptoms (SMD=0.61, 95% CI 0.40 to 0.83) for preschool children either with or without the child’s involvement Mulqueen JM et al., 2015, level I
- reduce oppositional behaviour, destructive behaviour and ADHD symptoms Charach A et al., 2013, level I
- reduce anxiety and depression, as well as internalising behaviour Zwi M et al., 2011, level I
- increase self-control behaviour Huang YH et al., 2015, level I

Parent training and behavioural intervention may need to be done continuously for overall benefits to be sustained. Huang YH et al., 2015, level I The intervention can be done individually or in groups. Other caregivers involved in the care of the child are encouraged to take part in the training and intervention.

Parent training is also recommended by other guidelines in ADHD. NICE, 2018; AMS, 2014; SIGN, 2009 The positive effect of behavioural therapy persists while positive effect of medications cease when the medication is stopped. AACAP, 2007

In view of the benefits of parent training, more local healthcare providers need to be trained to carry out the intervention. Refer Appendix 5 on Advice for Behavioural Management.

Recommendation 3

- Parent training and behavioural intervention should be offered in attention-deficit/hyperactivity disorders.
4.2.3 School-based intervention
School-based intervention is a strategy implemented in a classroom setting to improve the well-being of students. It reduces or prevents school-related difficulties. The intervention requires interdisciplinary coordination among healthcare providers and educational staff handling children with ADHD. Interventions may incorporate activities e.g. behavioral interventions and modifications to academic instructions.

A Health Technology Assessment showed that school-based intervention led to improvement in both core ADHD symptoms and academic outcome. Richardson M et al., 2015, level 1

i. average beneficial effect on core ADHD symptoms
   - neurocognitive assessment on inattention (Cohen’s d=0.44, 95% CI 0.18 to 0.70) and hyperactivity/impulsivity (Cohen’s d=0.33, 95% CI 0.13 to 0.53)
   - teacher-rated inattention assessed using various rating scales e.g. CRS, CRS-R, CBCL, ADHD-RS etc. (Cohen's d=0.60, 95% CI 0.14 to 1.06)

ii. small effect on externalising symptoms reported by teachers (Cohen’s d=0.28, 95% CI 0.04 to 0.53)

iii. small effect on perceptions of school-related adjustment as assessed by teachers (Cohen’s d=0.26, 95% CI 0.05 to 0.47)

NICE recommends that more education about ADHD be provided to trainee teachers. Teachers who have received training on ADHD and its management should provide behavioural interventions in the classroom to help children and young people with ADHD. NICE, 2018

American Academy of Pediatrics recommends that educational interventions and individualised instructional supports, including school environment, class placement, instructional placement and behavioural supports, are a necessary part of any treatment plan and they often include an Individualised Education Programme (IEP). AAP, 2019

**Recommendation 4**
- School-based interventions should be offered in attention-deficit/hyperactivity disorders.

Refer Appendix 6 on School-Based Intervention.

4.2.4 Others
Neurofeedback (NF) consists of measuring brain waves and providing a feedback signal which teaches self-control of brain functions. Marzbani H et al., 2016 An RCT showed NF led to small improvement in ADHD symptoms which were sustained at six months follow-up. Steiner NJ et al., 2014, level I The Canadian ADHD Practice Guidelines concludes that there is insufficient data to recommend NF as a standard treatment for ADHD. CADDRA, 2020

- There is insufficient evidence to support the use of NF in the treatment of ADHD.

4.3 Pharmacological Treatment

- Medication should be offered to children aged ≥6 years and adolescents with attention-deficit/hyperactivity disorder:
  - if their ADHD symptoms are persistent and causing significant impairment in at least one domain despite behavioural and environmental interventions. NICE, 2018
  - along with evidence-based training interventions and/or behavioural interventions, if available. AAP, 2019
Refer to Appendix 7 on Pharmacological Treatment of ADHD.

a. **Stimulants/Non-stimulants**

A Cochrane systematic review showed that methylphenidate (MPH), compared with placebo, in children and adolescents with ADHD reduced:

- teacher-rated ADHD symptoms (SMD = -0.77, 95% CI -0.90 to -0.64)
- independent assessor-rated ADHD symptoms (SMD = -0.64, 95% CI -0.89 to -0.39)
- parent-rated ADHD symptoms (SMD = -0.66, 95% CI -0.82 to -0.51)

In a meta-analysis of 11 RCTs in children and adolescents with ADHD, symptom improvement was higher with MPH compared to atomoxetine (ATX) (RR=1.14, 95% CI 1.09 to 1.20). However, on the ADHD-RS, improvement was seen only in inattention (SMD=-0.13, 95% CI -0.25 to -0.01) and not in the total and hyperactivity/impulsivity domains.

In comparison with placebo, patients on MPH had more non-serious adverse events (RR=1.29, 95% CI 1.10 to 1.51). MPH had less drowsiness (RR=0.17, 95% CI 0.11 to 0.26), nausea (RR=0.49, 95% CI 0.29 to 0.85) and vomiting (RR=0.41, 95% CI 0.27 to 0.63) but more insomnia (RR=2.27, 95% CI 1.63 to 3.15) compared with ATX.

In both meta-analyses the primary papers were of moderate quality.

National Institute for Health and Care Excellence (NICE) recommends offering MPH (either short- or long-acting) as first-line pharmacological treatment for children aged ≥5 years and young people with ADHD. ATX can be offered in those who:

- cannot tolerate MPH
- do not respond to separate 6-week trials of MPH, having considered alternative preparations and adequate doses

MPH and ATX are indicated for ADHD in children six years and older.

There is no current indication to perform an electrocardiogram (ECG) in a child prior to or during treatment using stimulants unless indicated by history or physical examination. Cardiac risk factors should be assessed, including history of congenital heart disease or arrhythmias, palpitations, exercise intolerance or chest pain, family history of early cardiac disease (<50 years of age) or unexplained sudden death and cardiovascular examination prior to initiating pharmacological treatment for ADHD.

**Recommendation 5**

- Methylphenidate should be offered to children aged ≥6 years and adolescents with Attention-deficit/ hyperactivity disorder, if medication is indicated*.
  - Atomoxetine may be used as an alternative.

*refer to yellow box above

b. **Others**

In a good network meta-analysis of 133 double-blind RCTs on children and adolescents with ADHD, the following medications were superior to placebo in reducing ADHD core symptoms as rated by clinicians:

- amphetamines (SMD = -1.02, 95% CI -1.19 to -0.85)
- ATX (SMD= -0.56, 95% CI -0.66 to -0.45)
- bupropion (SMD= -0.96, 95% CI -1.69 to -0.22)
- clonidine (SMD= -0.71, 95% CI -1.17 to -0.24)
• guanfacine (SMD=-0.67, 95% CI -0.85 to -0.50)
• MPH (SMD=-0.78, 95% CI -0.93 to -0.62)
• modafinil (SMD=-0.62, 95% CI -0.84 to -0.41)

By contrast, in comparisons based on teachers’ ratings, only MPH (SMD=-0.82, 95% CI -1.16 to -0.48) and modafinil (SMD=-0.76, 95% CI -1.15 to -0.37) were more efficacious than placebo.

In head to head comparisons, clinical ratings showed:
• amphetamines were superior to modafinil (SMD=-0.39, 95% CI -0.67 to -0.12), ATX (SMD=-0.46, 95% CI -0.65 to -0.27), and MPH (SMD=-0.24, 95% CI -0.44 to -0.05)
• ATX was inferior to MPH (SMD=0.22 95% CI 0.05 to 0.39)

With respect to tolerability, all study medications were inferior to placebo:
• amphetamines (OR=2.30, 95% CI 1.36 to 3.89)
• ATX (OR=2.30, 95% CI 1.36 to 3.89)
• bupropion (OR=1.51, 95% CI 0.17 to 13.27)
• clonidine (OR=4.52, 95% CI 0.75 to 27.03)
• guanfacine (OR=2.64, 95% CI 1.20 to 5.81)
• MPH (OR=1.44, 95% CI 0.90 to 2.31)
• modafinil (OR=1.34, 95% CI 0.57 to 3.18)

In head to head comparisons, MPH was more tolerable than ATX, amphetamines, guanfacine, clonidine and bupropion. However, the differences were not statistically significant.

c. **Treatment for Pre-schoolers (Children below six years old)**

There was no strong evidence retrieved for pre-schoolers with ADHD and the CPG DG acknowledges the concerns around the adverse effects of medication in this group.

NICE recommends not to offer medication to any child under five years without a second specialist opinion from an expert in managing ADHD in young children.\textsuperscript{NICE, 2018}

In the previous Malaysian CPG, the recommendation was that medication for pre-schoolers should be initiated by a child psychiatrist or a paediatrician familiar with the management of ADHD in this group.\textsuperscript{Moh, 2008}

---

**Recommendation 6**
- If medication for attention-deficit/hyperactivity disorder (ADHD) is indicated in children <6 years old, it should be initiated by a child psychiatrist or a paediatrician with expertise in managing ADHD.

---

**4.4 Combination Treatment**

Pharmacotherapy alone or in combination treatment (pharmacotherapy and non-pharmacological treatment) have been offered in ADHD. The combination of pharmacotherapy and behavioural therapy in ADHD allows for the use of lower stimulant dosages, which may reduce risk of medication-related side effects.\textsuperscript{AACAP, 2007}

---

**Recommendation 7**
- Combination treatment (pharmacological and non-pharmacological treatment) should be considered in children ≥6 years of age and adolescents with attention-deficit/hyperactivity disorder when the symptoms persist and cause functional impairment.
4.5 Dietary Modification

Dietary modification for ADHD is divided into elimination and supplementation diets.

The evidence for dietary modification in management of ADHD are mostly inconclusive. Elimination diet include removal of artificial food colourants, additives, sugar, artificial sweeteners and Few Foods Diet (FFD). FFD is a diet that excludes all but a few food items for a certain duration. It normally includes two types of meat, two sources of carbohydrates, two vegetables, two fruits, oil and water. Supplementation diet involve addition of amino acids, essential fatty acids, vitamins and minerals.\textsuperscript{Heilskov Rytter MJ et al., 2015, level I}

NICE recommends not to advise elimination of artificial colouring, additives and dietary fatty acid supplementations. There is also no evidence of long-term effectiveness of a FFD.\textsuperscript{NICE, 2018}

In the previous Malaysian CPG on ADHD, the recommendation was that parents should monitor and document the association between a particular food item and hyperactive behaviour in children with ADHD. The particular food item should be avoided if it is clearly associated with behavioural changes.\textsuperscript{Moh, 2008}

- There is insufficient evidence to recommend dietary modification in the treatment of ADHD.

5. TRADITIONAL AND COMPLEMENTARY MEDICATION

Traditional and complementary medication that were frequently studied in the management of ADHD include nutritional medicines (zinc, iron, omega-3, vitamin C and acetyl-L-carnitine) and herbal medicines [ginkgo, St. John’s wart, French maritime pine bark and Ningdong granule (traditional Chinese herbal formula)]. There is no clear evidence for recommendation of these medications in treating ADHD.\textsuperscript{Sarris J et al., 2011, level I}

A systematic review showed no evidence on the usefulness of medicinal cannabinoids for the treatment of ADHD in adults.\textsuperscript{Black N et al., 2019, level I}

6. SPECIAL POPULATION

6.1 Transition

A majority (60 - 85%) of children with ADHD will continue to meet criteria for the disorder during their teenage and adult years.\textsuperscript{AACAP, 2007} However, ADHD treatment rates decline sharply from childhood through young adulthood.\textsuperscript{Treu T et al., 2016, level III} The decline in treatment is caused by the perception that adolescents with ADHD do not meet diagnostic criteria and, therefore, do not require the treatment.\textsuperscript{Robb A et al., 2013, level III} The treatment discontinuance is also due to the lack of clarity on service availability and no provision of transitional care for the patients.\textsuperscript{Treu T et al., 2016, level III}

A majority (60 - 85%) of children with ADHD will continue to meet criteria for the disorder during their teenage and adult years.\textsuperscript{AACAP, 2007} However, ADHD treatment rates decline sharply from childhood through young adulthood.\textsuperscript{Treu T et al., 2016, level III} The decline in treatment is because:
there is an interruption in management of the disorder when adolescent patients transit to adult health care services as there is no provision of transitional care for the patients\(^\text{Treuer T et al., 2016, level III}\)
of the believe that ADHD resolves during adolescence and young adulthood with minimal impact in functioning\(^\text{Kooji}\)
of the perception that adolescents with ADHD do not meet diagnostic criteria and, therefore, do not require the treatment\(^\text{Robb A et al., 2013, level III}\)
the presentation is masked by the presence of comorbid psychiatric syndromes\(^\text{Kooji}\)
there is a limited service availability\(^\text{Treuer T et al., 2016, level III}\)
clinicians are not well equipped to handle adults with ADHD\(^\text{Treuer T et al., 2016, level III}\)
the stigma and myths about ADHD and its treatment\(^\text{Kooji}\)

Symptoms of ADHD in adolescence and adulthood:\(^\text{Kooji}\)
- may alter; hyperactivity and impulsivity are less evident, but the inattention symptoms remain
- show prominent impairment in executive functioning
- are complicated by the presence of comorbid psychiatric symptoms
- are associated with continued clinical and psychosocial impairments

- Optimising services during childhood and transition to adult health care improves treatment and prognosis of individuals with ADHD.

**Recommendation 8**
- Children with attention-deficit/hyperactivity disorder should continue to receive treatment throughout their lifespan.

### 6.2. Adults

Observational studies of childhood outcomes of ADHD suggested persistence of symptoms into adulthood. Inattention symptoms remained prominent, while symptoms of hyperactivity and impulsivity may persist, decline or change in their presentation.\(^\text{Klein RG et al., 2012, level II-2}\) ADHD persistence rates from childhood to adulthood ranged from 40 - 50%.\(^\text{Sibley MH et al., 2016, level III}\)

**a. Risk factors for persistence of ADHD into adulthood**

A meta-analysis of 16 studies found that the risk factors for persistence of ADHD into adulthood were: \(^\text{Caye A et al., 2016, level II-2}\)
- severity of ADHD (OR=2.33, 95% CI 1.60 to 3.39)
- CD (OR=1.85, 95% CI 1.06 to 3.24)
- major depressive disorder (MDD) (OR=1.80, 95% CI 1.10 to 2.95)
- parental psychopathology
  - paternal anxiety-mood disorder (OR=2.40, 95% CI 1.10 to 5.50)
  - parental (mother or father) antisocial personality disorder (OR=2.20, 95% CI 1.20 to 4.20)

The same meta-analysis showed that factors not significantly associated with the persistence of ADHD into adulthood were gender, socioeconomic status at childhood, intelligence quotient (IQ), ODD, exposure to trauma and adversities e.g. single parent families.\(^\text{Caye A et al., 2016, level II-2}\)

**b. Co-morbidities**

In a small cross-sectional study on individuals aged 17 to 74 years old, adults with ADHD had significantly higher rates of DSM-IV Axis I (46.9%) and Axis II (27.31%) co-morbidities compared with non-ADHD adults.\(^\text{Cumyn, L et al., 2009, level III}\)
Among adults with ADHD, those with ADHD-C (combined hyperactivity and inattention) had significantly higher rates of past and current MDD and anxiety disorders compared with ADHD-I (inattention). They also had significantly higher rates of past CD and antisocial personality disorder. Cumyn, L et al., 2009, level III

c. Outcome of childhood ADHD
Adults with childhood ADHD, compared with those without ADHD, had higher risk of:

• academic difficulties Erskine HE et al., 2016, level II-2
  o grade retention (OR=3.64, 95% CI 2.39 to 5.56)
  o school suspension (OR=6.31, 95% CI 2.53 to 15.73)
  o increased use of education services (OR=6.37, 95% CI 2.58 to 15.73)
  o failure to finish high school (OR=3.70, 95% CI 1.96 to 6.99)

• psychiatric disorders Erskine HE et al., 2016, level II-2
  o ODD (OR=7.05, 95% CI 2.63 to 18.85)
  o CD (OR=5.40, 95% CI 2.53 to 11.55)
  o antisocial disorder (OR=2.83, 95% CI 1.23 to 6.52)
  o depression (OR=2.31, 95% CI 1.45 to 3.70)
  o use of mental health services (OR=2.35, 95% CI 1.42 to 3.89)

• substance and alcohol use Lee SS et al., 2011, level II-2
  o lifetime nicotine use (OR=2.08, 95% CI 1.66 to 2.60)
  o lifetime marijuana use (OR=2.78, 95% CI 1.64 to 4.74)
  o nicotine abuse/dependence (OR=2.82, 95% CI 2.41 to 3.29)
  o alcohol use disorder (OR=1.74, 95% CI 1.38 to 2.20)
  o marijuana abuse/dependence (OR=1.58, 95% CI 1.16 to 2.14)
  o cocaine abuse/dependence (OR=2.05, 95% CI 1.38 to 3.04)
  o general illicit drug abuse/dependence (OR=2.64, 95% CI 1.77 to 3.94)

• legal issues Erskine HE et al., 2016, level II-2
  o arrests (OR=2.43, 95% CI 1.62 to 3.65)
  o convictions (OR=2.01, 95% CI 1.25 to 3.24)
  o vehicular-accidents-at-faults (OR=1.98, 95% CI 1.03 to 3.81)

• problems in other areas of life Shaw M et al., 2012, level II-2
  o social function
  o low self-esteem
  o less likely to stay married (p<0.001) Klein RG et al., 2012, level II-2
  o lower salary (p<0.001) Klein RG et al., 2012, level II-2
  o lower work functioning (p<0.001) Klein RG et al., 2012, level II-2
  o poorer social economic status (p<0.001) Klein RG et al., 2012, level II-2
  o obesity Shaw M et al., 2012, level II-2

Adults with ADHD who received treatment in childhood compared to those who did not, had higher academic attainment and employment, lower rates of lifetime occurrence of depression, anxiety and bipolar disorder. Halmoy A et al., 2009, level II-2 They also had better outcomes in driving, obesity, self-esteem, social function and drug use/addictive behaviour. Shaw M et al., 2012, level II-2

• In the management of adults with ADHD, the assessment and treatment of ADHD, comorbidities and psychosocial complications are crucial.
**Recommendation 9**
- Any child or adolescent presenting with academic difficulties, behavioural problems, mood disturbances, substance use or personality disorders should be evaluated for attention-deficit/hyperactivity disorder to prevent deleterious outcomes in adulthood.

7. **REFERRAL**

In view of no retrievable evidence on referral criteria for ADHD, the CPG development group proposes the following terms for referral.

- Patients presenting with core symptoms of inattention and/or hyperactivity and impulsivity in primary care should be referred for evaluation of ADHD by family medicine specialists.
- Primary care providers should refer patients with ADHD to the psychiatrist/paediatrician when there is:
  - uncertainty of diagnosis
  - lack of response to non-pharmacological treatment
  - indication to start pharmacotherapy
  - severe side effects of medication
  - co-morbidities (e.g. substance abuse)
- All pre-schoolers (below six years of age) with suspicion of ADHD should be referred to the child psychiatrist or a paediatrician with expertise in managing ADHD for further management.

8. **MONITORING AND FOLLOW-UP**

Clinicians should provide regular follow-up for individuals with ADHD. During the follow-up, emphasise treatment adherence and, monitor the effectiveness and side effects of medication if prescribed. NICE, 2018

The following parameters should be monitored during follow-up:
- height and weight
- cardiovascular assessment
- tics
- seizure
- sleep
- worsening behaviour
- stimulant diversion

Refer to Appendix 8 for further information.

In addition, for children aged 12 years and above, clinicians should assess for changes in mood and, presence of risky behaviours e.g. intentional self-harm, substance use and, suicidal and risky sexual behaviours. AAP, 2019; AACAP, 2007

If a child or adolescent’s growth over time is significantly affected by medication (i.e. they have weight loss and/or have not met the height expected for their age) consider a planned break in treatment over school holidays to allow “catch-up” growth. NICE, 2018
If a patient with ADHD has been symptom free for at least one year, enquiries should be made on whether the patient and family still think the medication is beneficial. If the decision is made to discontinue the medication, it should be done at a low-stress time. **AACAP, 2007**

Parents and adolescents with ADHD are encouraged to discuss any preferences to stop or change medication and to be involved in any decision about stopping treatment. **NICE, 2018** Medications should be restarted in the event of any recurrence of symptoms.

- Children with ADHD are eligible to get additional support e.g.:
  - registration for Orang Kurang Upaya (OKU) with Social Welfare Department (Jabatan Kebajikan Masyarakat),
  - special needs education under District Education Department (Pejabat Pendidikan Daerah)
  - examination and classroom accommodation (e.g. extra time, reduced distraction)

### Recommendation 10
- Healthcare providers should provide continued care and long-term monitoring to children and adolescents with attention-deficit/hyperactivity disorder.

### 9. IMPLEMENTING THE GUIDELINES

The management of ADHD should be guided by evidence-based approach in order to provide quality care to the patients. Several factors may affect the implementation of recommendations in the CPG.

#### a. Facilitating and Limiting Factors

Existing facilitators for application of the recommendations in the CPG include:
- wide dissemination of the CPG (soft- and hardcopies) to healthcare providers
- training and updates on ADHD
- public awareness campaigns related to mental health

Existing barriers for application of the recommendations of the CPG are:
- limited exposure and training among healthcare providers on management of ADHD
- variation in availability of expertise and access to service provision due to financial constraints
- lack of awareness among patients, families and educators on ADHD

#### b. Potential Resource Implications

In local scenario, children with ADHD are often missed. Adults and peers often consider the children as having behavioural problems, not listening and not putting in effort. They are often labelled, isolated, ignored or punished.

There are also negative perceptions regarding ADHD e.g.:
- it is not a medical illness
- the medications increase the risk of substance use
- the condition will disappear as the child gets older
- boys are usually hyperactive anyway
- only boys have ADHD

The CPG recommends early detection and referral, comprehensive assessment and treatment of the disorder. This requires increased awareness among parents, educators and
healthcare providers to establish diagnosis and embark on intervention early. Collaboration with various experts and agencies is required to provide optimal management e.g. psychological and behavioural intervention, parent and teachers training, and classroom accommodation.

Thus, the implementation of this CPG requires resources to provide:
- training of healthcare providers and educators
- assessment and intervention tools
- better access to pharmaco- and non-pharmacological therapy
- access to policy makers

The following is proposed as clinical audit indicator for quality management of ADHD:

\[
\frac{\text{Number of newly diagnosed children and adolescents with ADHD offered parent training and behavioural intervention}}{\text{Number of newly diagnosed children and adolescents with ADHD in the same period}}
\]

\[
\frac{\text{Number of children ≥6 years diagnosed with ADHD prescribed methylphenidate (MPH) when indicated*}}{\text{Number of children ≥6 years diagnosed with ADHD and indicated for MPH in the same period}}
\]

*if their ADHD symptoms are persistent and causing significant impairment in at least one domain despite behavioural and environmental interventions

Implementation strategies will be developed following the approval of the CPG by MoH which include launching of the CPG, Quick Reference and Training Module.
References


Graziano PA, Garcia AM, Landis TD. To Fidget or Not to Fidget, That Is the Question: A Systematic Classroom Evaluation of Fidget Spinners Among Young Children With ADHD. J Atten Disord. 2018;1087054718770009.


Hamilton R, Gray C, Belanger SA, et al. Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society,


Medication Guide. Ritalin® (methylphenidate hydrochloride, USP) tablets CII. (Available at https://www.fda.gov/media/72922/download)


EXAMPLE OF SEARCH STRATEGY

Clinical Question: What are the safe and effective pharmacological treatments for ADHD? - Stimulants

1. ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY/
2. (attention deficit adj2 disorder*).tw.
3. attention deficit disorder* with hyperactivity.tw.
4. ((attention deficit hyperactivity or attention deficit-hyperactivity) adj3 disorder*).tw.
5. (hyperkinetic adj1 syndrome*).tw.
6. adhd.tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. CENTRAL NERVOUS SYSTEM STIMULANTS/
9. (analeptic adj1 (agent* or drug*)).tw.
10. analeptic*.tw.
11. central nervous system stimulant*.tw.
12. METHYLPHENIDATE/
13. methylphenidate.tw.
14. (methylphenidate adj1 hydrochloride).tw.
15. ritalin.tw.
16. ritalin sr.tw.
17. ritalin-sr.tw.
18. concerta.tw.
19. ritalin LA.tw.
20. adderall.tw.
21. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22. 7 and 21
23. limit 22 to (english language and humans and yr=2008-Current and "all child (0 to 18 years)")
Appendix 2

CLINICAL QUESTIONS

1. Risk Factors
   - What are the risk factors for ADHD?

2. Diagnosis
   - What are the accurate screening instruments for ADHD?
   - What are the accurate diagnostic criteria and diagnostic instruments for ADHD?
   - What are the accurate supporting investigations for the diagnosis of ADHD?
   - What are the associated co-morbidities of ADHD?

3. Treatment
   - What are the safe and effective non-pharmacological treatments for ADHD?
     - Psychoeducation
     - Behavioural therapy
       - Individual
       - Family-based
       - School-based
     - Assistive technology
   - What are the safe and effective pharmacological treatments for ADHD?
     - Stimulants
     - Non-stimulants
     - Others
   - What are the appropriate assessments for pre-pharmacological treatment in ADHD?
   - What are the safe and effective pharmacological treatments for pre-schoolers with ADHD?
   - What are the safe and effective traditional and complementary medication in ADHD?
   - What are the safe and effective dietary modification in ADHD?

4. Special populations
   - Transition
   - Adults

5. Referral
   - What are the referral criteria of children with ADHD to the following services:
     - Primary care
     - Secondary/tertiary care

6. Monitoring and follow-up
   - What are the effective follow-up and monitoring practices in ADHD?
   - What is the safety and effectiveness of drug holiday in ADHD?
Appendix 3

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDER FIFTH EDITION
(DSM-5)

Attention-Deficit/Hyperactivity Disorder

Diagnostic Criteria

A. A persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development, as characterized by (1) and/or (2):

1. **Inattention:** Six (or more) of the following symptoms have persisted for at least 6 months to a degree that is inconsistent with developmental level and that negatively impacts directly on social and academic/occupational activities:
   
   **Note:** The symptoms are not solely a manifestation of oppositional behavior, defiance, hostility, or failure to understand tasks or instructions. For older adolescents and adults (age 17 and older), at least five symptoms are required.
   
   a. Often fails to give close attention to details or makes careless mistakes in schoolwork, at work, or during other activities (e.g., overlooks or misses details, work is inaccurate).
   
   b. Often has difficulty sustaining attention in tasks or play activities (e.g., has difficulty remaining focused during lectures, conversations, or lengthy reading).
   
   c. Often does not seem to listen when spoken to directly (e.g., mind seems elsewhere, even in the absence of any obvious distraction).
   
   d. Often does not follow through on instructions and fails to finish schoolwork, chores, or duties in the workplace (e.g., starts tasks but quickly loses focus and is easily side tracked).
   
   e. Often has difficulty organizing tasks and activities (e.g., difficulty managing sequential tasks; difficulty keeping materials and belongings in order; messy, disorganized work; has poor time management; fails to meet deadlines).
   
   f. Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (e.g., schoolwork or homework; for older adolescents and adults, preparing reports, completing forms, reviewing lengthy papers).
   
   g. Often loses things necessary for tasks or activities (e.g., school materials, pencils, books, tools, wallets, keys, paperwork, eyeglasses, mobile telephones).
   
   h. Is often easily distracted by extraneous stimuli (for older adolescents and adults, may include unrelated thoughts).
   
   i. Is often forgetful in daily activities (e.g., doing chores, running errands; for older adolescents and adults, returning calls, paying bills, keeping appointments).

2. **Hyperactivity and impulsivity:** Six (or more) of the following symptoms have persisted for at least 6 months to a degree that is inconsistent with developmental level and that negatively impacts directly on social and academic/occupational activities:

   **Note:** The symptoms are not solely a manifestation of oppositional behavior, defiance, hostility, or a failure to understand tasks or instructions. For older adolescents and adults (age 17 and older), at least five symptoms are required.

   a. Often fidgets with or taps hands or feet or squirms in seat.
   
   b. Often leaves seat in situations when remaining seated is expected (e.g., leaves his or her place in the classroom, in the office or other workplace, or in other situations that require remaining in place).
   
   c. Often runs about or climbs in situations where it is inappropriate. (**Note:** In adolescents or adults, may be limited to feeling restless.)
   
   d. Often unable to play or engage in leisure activities quietly.
e. Is often “on the go,” acting as if “driven by a motor” (e.g., is unable to be or uncomfortable being still for extended time, as in restaurants, meetings; may be experienced by others as being restless or difficult to keep up with).

f. Often talks excessively.

g. Often blurts out an answer before a question has been completed (e.g., completes people’s sentences; cannot wait for turn in conversation).

h. Often has difficulty waiting his or her turn (e.g., while waiting in line).

i. Often interrupts or intrudes on others (e.g., butts into conversations, games, or activities; may start using other people’s things without asking or receiving permission; for adolescents and adults, may intrude into or take over what others are doing).

B. Several inattentive or hyperactive-impulsive symptoms were present prior to age 12 years.

C. Several inattentive or hyperactive-impulsive symptoms are present in two or more settings (e.g., at home, school, or work; with friends or relatives; in other activities).

D. There is clear evidence that the symptoms interfere with, or reduce the quality of, social, academic, or occupational functioning.

E. The symptoms do not occur exclusively during the course of schizophrenia or another psychotic disorder and are not better explained by another mental disorder (e.g., mood disorder, anxiety disorder, dissociative disorder, personality disorder, substance intoxication or withdrawal).

Specify whether:

314.01 (F90.2) Combined presentation: If both Criterion A1 (inattention) and Criterion A2 (hyperactivity-impulsivity) are met for the past 6 months.

314.00 (F90.0) Predominantly inattentive presentation: If Criterion A1 (inattention) is met but Criterion A2 (hyperactivity-impulsivity) is not met for the past 6 months.

314.01 (F90.1) Predominantly hyperactive/impulsive presentation: If Criterion A2 (hyperactivity-impulsivity) is met and Criterion A1 (inattention) is not met for the past 6 months.

Specify if:

in partial remission: When full criteria were previously met, fewer than the full criteria have been met for the past 6 months, and the symptoms still result in impairment in social, academic, or occupational functioning.

Specify current severity:

Mild: Few, if any, symptoms in excess of those required to make the diagnosis are present, and symptoms result in no more than minor impairments in social or occupational functioning.

Moderate: Symptoms or functional impairment between “mild” and “severe” are present.

Severe: Many symptoms in excess of those required to make the diagnosis, or several symptoms that are particularly severe, are present, or the symptoms result in marked impairment in social or occupational functioning.

F90 Hyperkinetic disorders

A group of disorders characterized by an early onset (usually in the first five years of life), lack of persistence in activities that require cognitive involvement, and a tendency to move from one activity to another without completing any one, together with disorganized, ill-regulated, and excessive activity. Several other abnormalities may be associated. Hyperkinetic children are often reckless and impulsive, prone to accidents, and find themselves in disciplinary trouble because of unthinking breaches of rules rather than deliberate defiance. Their relationships with adults are often socially disinhibited, with a lack of normal caution and reserve. They are unpopular with other children and may become isolated. Impairment of cognitive functions is common, and specific delays in motor and language development are disproportionately frequent. Secondary complications include dissocial behaviour and low self-esteem.

Excl.: anxiety disorders (F41.-)
      mood [affective] disorders (F30-F39)
      pervasive developmental disorders (F84.-)
      schizophrenia (F20.-)

F90.0 Disturbance of activity and attention

Attention deficit:
- disorder with hyperactivity
- hyperactivity disorder
- syndrome with hyperactivity

Excl.: hyperkinetic disorder associated with conduct disorder (F90.1)

F90.1 Hyperkinetic conduct disorder
Hyperkinetic disorder associated with conduct disorder

F90.8 Other hyperkinetic disorders

F90.9 Hyperkinetic disorder, unspecified
Hyperkinetic reaction of childhood or adolescence NOS
Hyperkinetic syndrome NOS

ADVICE FOR BEHAVIOURAL MANAGEMENT

General advice for parents
1. Remain calm and in control.
2. Schedule one on one time, at least 10 to 15 minutes every day with your child to let him/her know how important he or she is to you.
3. Children with ADHD benefit from frequent feedback. Notice your child’s strength and praise him/her regularly.
4. Model the behaviour you would like to see from your child.
5. Use schedules and routines.
6. Post lists and reminders for the routines in places they will be seen.
7. Discuss the behavioural goals with your child.
8. Discuss the behavioural target(s), expectation and feedback with your child’s other caregivers so he/she gets a consistent message.
9. Target one to two behaviours that you want to change at one time.
10. Give directions one at a time and track your child’s response.
11. Use desired activities (screen time/play) as privileges/rewards for success on behavioural targets.
12. Ensure regular mealtimes and good rest for your child and you.

Younger Children
1. Routines are very important. Balance higher energy and quieter activities throughout the day.
2. Use visual prompts in the order of routines you would like him/her to learn (e.g. steps to get ready for bed).
3. Choose your battles - ignore minor misbehaviours.
4. Give choices but limit the number.
5. Use and reinforce “rules” (e.g. keeping hands to self) immediately before venturing into a community setting.
6. Prepare your child before an outing (e.g. crowded areas, in the car)

School-age child at home
1. Include homework/study time as a part of the family routine in a non-distracting place.
2. Check your child’s school schedule every day and help him/her organise the homework into doable portions.
3. Help your child use a system (e.g. labelled folders for each subject) to get the homework back to school.
4. Plan brief breaks between the homework portions.
5. Use the activities your child enjoys as incentives for getting work done (homework and chores).
6. Consider getting one to one help for your child’s schoolwork.
7. Help the child to be mindful of his/her deadlines.
8. Communicate with your child’s teacher about homework, grades, and behaviour.
9. If your child is struggling, consider requesting for special education.
10. Invite peers one at a time to reduce stimulation and encourage appropriate social behaviours.

Appendix 6

SCHOOL-BASED INTERVENTION

The following are suggestions for implementation of school-based intervention programme.

• Have consistent rules and expectations with predictable classroom settings.
• Allow regular breaks.
• Place the child near the teacher and away from distractions (e.g. windows and doors).
• Give short and simple instructions.
• Periodically check to see if the child stays focused.
• Teach the child time management and study skills.
• Reduce the need for the children to copy assignments from the board. Instead use handouts and worksheets.
• Establish a daily communication method between school and home regarding targeted behaviours and learning tasks (e.g. homework).
• Allow extra time to complete tasks especially in tests and examinations.
• Praise and reward performance and good behaviour.
• Refrain from using verbal or physical punishments.
• Consider allowing computers or other digital devices to help the child in the learning process.

## PHARMACOLOGICAL TREATMENT OF ADHD

<table>
<thead>
<tr>
<th>Drug/Type</th>
<th>Minimum Dose</th>
<th>Maximum Dose</th>
<th>Titration and Timing</th>
<th>Duration of Action</th>
<th>Common Effects</th>
<th>Adverse Effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylphenidate HCL 10 mg Immediate-release (IR) tablet</td>
<td>Children over six years and adolescents: Initial 5 mg 1 - 2 times daily</td>
<td>Total daily dose 60 mg/day (in 2 to 3 divided doses), not to exceed 2 mg/kg/day</td>
<td>Increase by 5 - 10 mg daily at weekly intervals</td>
<td>3 - 5 hours</td>
<td>Headache, insomnia, irritability, decreased appetite, xerostomia, nausea, increased heart rate</td>
<td>It is advisable to have a meal before taking the medication if patient develops loss of appetite as a side effect</td>
<td>Avoid dosing late in the day because of risk of insomnia</td>
</tr>
<tr>
<td>Methylphenidate HCL 18 mg, 27 mg*, 36 mg Extended-release (ER) tablet</td>
<td>Children over six years and adolescents: 18 mg once daily</td>
<td>Total 72 mg once daily</td>
<td>Increase by 18 mg at weekly intervals</td>
<td>8 - 12 hours</td>
<td></td>
<td></td>
<td>Conversion from IR to ER: • IR 5 mg 2 to 3 times daily: ER 18 mg once every morning • IR 10 mg 2 to 3 times daily: ER 36 mg once every morning • IR 15 mg 2 to 3 times daily: ER 54 mg once every morning • IR 20 mg 2 to 3 times daily: ER 72 mg once every morning</td>
</tr>
<tr>
<td>Methylphenidate HCl 20 mg, 30 mg*, 40 mg Long-acting (LA) capsule</td>
<td>Children over six years and adolescents: 20 mg once daily</td>
<td>Total 60 mg/day</td>
<td>May increase 10 mg daily at weekly intervals</td>
<td>6 - 8 hours</td>
<td></td>
<td></td>
<td>Conversion from IR to LA: Use equivalent total daily dose administered once daily Refer to product insert for porcine/bovine origin of gelatine capsule</td>
</tr>
<tr>
<td>Drug/Type</td>
<td>Minimum Dose</td>
<td>Maximum Dose</td>
<td>Titration and Timing</td>
<td>Duration of Action</td>
<td>Common Adverse Effects</td>
<td>Adverse Effects</td>
<td>Comments</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>----------------------</td>
<td>--------------------</td>
<td>------------------------</td>
<td>-----------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Atomoxetine HCl 10 mg, 18 mg, 25 mg, 40 mg, 60 mg capsule</td>
<td>Children over six years and adolescents: ≤70 kg: Initial dose 0.5 mg/kg/day once daily</td>
<td>1.4 mg/kg/day or 100 mg, whichever is less</td>
<td>Increase after minimum of three days to 1.2 mg/kg/day</td>
<td>Up to 24 hours</td>
<td>Headache, insomnia, drowsiness, hyperhidrosis, xerostomia, nausea, decreased appetite, abdominal pain, vomiting, constipation</td>
<td>Renal impairment: No dosage adjustment necessary</td>
<td>Hepatic impairment: Mild: No dosage adjustment. Moderate: Reduce to 50% of normal dose. Severe: Reduce to 25% of normal dose</td>
</tr>
<tr>
<td></td>
<td>Children over six years and Adolescents: &gt;70 kg: Initial dose 40 mg once daily</td>
<td>100 mg/day</td>
<td>Increase after minimum of three days to 80 mg/day</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*not listed in MoH Formulary

**Source:**
2. Wolters Kluwer Clinical Drug Information, Inc. UpToDate® [Mobile application software]
### MANAGEMENT OF COMMON ADVERSE EFFECTS ASSOCIATED WITH STIMULANT USE IN ADHD

<table>
<thead>
<tr>
<th>ADVERSE EFFECTS</th>
<th>MONITORING AND ADVICE</th>
</tr>
</thead>
</table>
| Weight loss                   | - Children $\leq 10$ years old: measure weight every three months after starting treatment  
- Children $>10$ years old: measure weight at three and six months after starting treatment and, every six months thereafter or more often if concerns arise  
- Advise taking medication either with or after food, rather than before meals  
- Take additional meals early in the morning or late in the evening after medications effects have worn off  
- Take a planned break from treatment (drug holiday)  
- Change medication                                                                 |
| Linear growth impairment      | - Measure height every six months in children and adolescents  
- Consider drug holiday                                                                                                                                             |
| Insomnia                      | - Monitor changes in sleep pattern (e.g. with a sleep diary)  
- Adjust medication accordingly                                                                                                                                          |
| Palpitation (tachycardia)     | - Monitor heart rate and blood pressure and, compare with the normal range for age before and after each dose change and every six months  
- ECG is not indicated unless there is clinical indication  
- If there is persistent tachycardia, reduce the dose and may refer to paediatrician or physician |
| Tics                          | - Consider if the tics are related to the stimulant (tics naturally wax and wane)  
- Observe and if it worsens may consider non-stimulant medications                                                                                                           |
| Seizures                      | - Review ADHD medication and stop any medication that might be contributing to the seizures  
- After investigation and if ADHD medication is unlikely to cause the seizures, may cautiously reintroduce the medication or consider non-stimulant medications |
| Worsening behaviour           | - Monitor the behaviour response to medication  
- If behaviour worsens, adjust medication and review diagnosis                                                                                                           |

Adapted: National Institute for Health and Clinical Excellence. Attention Deficit Hyperactivity Disorder: Diagnosis and Management (NG87). London, NICE, 2018
## LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADHD</td>
<td>attention-deficit/hyperactivity disorder</td>
</tr>
<tr>
<td>ADHD-C</td>
<td>ADHD, combined type</td>
</tr>
<tr>
<td>ADHD-I</td>
<td>ADHD, inattentive type</td>
</tr>
<tr>
<td>ADHD-RS</td>
<td>ADHD rating scale</td>
</tr>
<tr>
<td>ASD</td>
<td>autism spectrum disorder</td>
</tr>
<tr>
<td>ASQ</td>
<td>Abbreviated symptom questionnaire</td>
</tr>
<tr>
<td>ATX</td>
<td>atomoxetine</td>
</tr>
<tr>
<td>CBCL</td>
<td>Child behavioural checklist</td>
</tr>
<tr>
<td>CBCL-AP</td>
<td>Child behavioural checklist - Attention problem</td>
</tr>
<tr>
<td>CD</td>
<td>conduct disorder</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CO-OP</td>
<td>cognitive orientation to daily occupational performance</td>
</tr>
<tr>
<td>CPG</td>
<td>clinical practice guidelines</td>
</tr>
<tr>
<td>CQ(s)</td>
<td>clinical question(s)</td>
</tr>
<tr>
<td>CRS-R</td>
<td>Conners rating scale - revised</td>
</tr>
<tr>
<td>DSM-5</td>
<td>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition</td>
</tr>
<tr>
<td>DSM-IV</td>
<td>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>EEG</td>
<td>electroencephalogram</td>
</tr>
<tr>
<td>e.g.</td>
<td>example</td>
</tr>
<tr>
<td>ER</td>
<td>extended release</td>
</tr>
<tr>
<td>FFD</td>
<td>few foods diet</td>
</tr>
<tr>
<td>HCl</td>
<td>hydrochloride</td>
</tr>
<tr>
<td>HR</td>
<td>Hazard ratio</td>
</tr>
<tr>
<td>ICD-10</td>
<td>10th Revision of the International Statistical Classification of Diseases and Related Health Problem</td>
</tr>
<tr>
<td>IQ</td>
<td>intelligence quotient</td>
</tr>
<tr>
<td>IR</td>
<td>immediate release</td>
</tr>
<tr>
<td>kg</td>
<td>kilogramme</td>
</tr>
<tr>
<td>LA</td>
<td>long-acting</td>
</tr>
<tr>
<td>MDD</td>
<td>major depressive disorder</td>
</tr>
<tr>
<td>mg</td>
<td>miligramme</td>
</tr>
<tr>
<td>MPH</td>
<td>methylphenidate</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>NF</td>
<td>neurofeedback</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Health and Care Excellence</td>
</tr>
<tr>
<td>NOS</td>
<td>not otherwise specified</td>
</tr>
<tr>
<td>ODD</td>
<td>oppositional defiance disorder</td>
</tr>
<tr>
<td>OR</td>
<td>odds ratio</td>
</tr>
<tr>
<td>p</td>
<td>p-value</td>
</tr>
<tr>
<td>RCT(s)</td>
<td>randomised controlled trial(s)</td>
</tr>
<tr>
<td>RR</td>
<td>risk ratio</td>
</tr>
<tr>
<td>SDQ</td>
<td>Strengths and difficulties questionnaire</td>
</tr>
<tr>
<td>SMD</td>
<td>standardised mean difference</td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENT

The DG members of these guidelines would like to express their gratitude and appreciation to the following for their contributions:

- Panel of external reviewers who reviewed the draft
- Technical Advisory Committee of CPG for their valuable input and feedback
- Health Technology Assessment and Clinical Practice Guidelines Council for approving the CPG
- Dr Toh Chin Lee, Senior Consultant Psychiatrist, on the development of the CPG
- Dr Junainah Sabirin, Consultant Public Health Physician, on the development of the CPG
- Ms. Zamilah Mat Jusoh@Yusof on retrieval of evidence
- All those who have contributed directly or indirectly to the development of the CPG

DISCLOSURE STATEMENT

The panel members of both DG and RC had completed disclosure forms. None held shares in pharmaceutical firms or acts as consultants to such firms. Details are available upon request from the CPG Secretariat.

SOURCE OF FUNDING

The development of the CPG on Management of Attention-deficit/Hyperactivity Disorder in Children and Adolescents (Second Edition) was supported financially in its entirety by the MoH Malaysia.